// App-Quantinova.ai

P1-19-29 : An integrated safety analysis of talazoparib monotherapy from five clinical trials (phase 1‑3) in advanced cancers

Researchers

Presenter

  • Joannes Ettl

Principal Investigators

  • Jennifer Litton

  • Hope S. Rugo

  • Lida Mina

  • Miguel Martin

  • Nicholas Turner

  • Henri Roch

  • Zev Wainberg

  • Johann de Bono

  • Tiziana Usari

  • Mohamed Elmeliegy

  • Silvana Lanzalone

  • Akos Czibere

  • Liza DeAnnuntis

  • Sara A. Hurvitz

Medical Centers

  • Department of Obstetrics and Gynecology, Klinikum rechts der Isar, Technische Universitat Munchen, Munich, Germany

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

  • Banner MD Anderson Cancer Center, Mesa, AZ

  • Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Universidad Complutense, CiberOnc, GEICAM, Madrid, Spain

  • Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom

  • Institut Universitaire du Cancer de Toulouse, Toulouse, France

  • University of California, Los Angeles, Los Angeles, CA

  • Pfizer Inc, Milan, Italy

  • Pfizer Oncology, La Jolla, CA

  • Pfizer Inc., Cambridge, MA

  • Pfizer Inc, Collegeville, PA

  • University of California, Los Angeles and the Jonsson Comprehensive Cancer Center, Los Angeles, CA

Locations

  • Germany

  • United States

  • Spain

  • United Kingdom

  • France

  • Italy

Companies

  • PharmAbcine Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

  • Unspecified Cancer

Biomarkers

  • Breast cancer type 1 susceptibility protein

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • Talazoparib

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

Phase

  • I

Study Id's

  • NCT01945775

  • NCT02034916

  • NCT01286987

  • NCT03042910

  • NCT02921919

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved